Home/Pipeline/Bone Marrow Conditioning Program

Bone Marrow Conditioning Program

Not Specified

PipelineMentioned

Key Facts

Indication

Not Specified

Phase

Pipeline

Status

Mentioned

Company

Telix Pharmaceuticals

About Telix Pharmaceuticals

Telix Pharmaceuticals is a leader in the radiopharmaceutical space, focused on delivering precision oncology through targeted radiation. The company has achieved commercial success with its prostate cancer imaging agent Illuccix® and is advancing a deep pipeline of theranostic candidates, including its pivotal Phase III therapy program for prostate cancer (ProstACT). With a global operational footprint, including a major manufacturing facility in Belgium, Telix is positioned to scale its innovative platform across multiple high-need cancer indications.

View full company profile

Therapeutic Areas

Urologic Oncology Neuro-Oncology Musculoskeletal Oncology Bone Marrow Conditioning

Other Not Specified Drugs

Drug	Company	Phase	Status
Inflammation Programs	Arcus Biosciences	Not Specified	Plans outlined for 2026
AGMB-447	Agomab Therapeutics	Not Disclosed	Active
AGMB-101	Agomab Therapeutics	Not Disclosed	Active
TRIFERTY-ATM®	Laboratorio Reig Jofre	Approved/Commercial	Co-development completed
AGEN1571 (anti-ILT2)	Agenus	Not specified	Pipeline asset
AGEN1777	Agenus	Not specified	Pipeline asset
AGEN1721	Agenus	Not specified	Pipeline asset
INCAGN1876 (GITR Agonist)	Agenus	Not specified	Pipeline asset
INCAGN1949 (OX40 Agonist)	Agenus	Not specified	Pipeline asset
AGEN1327 (anti-TIGIT)	Agenus	Not specified	Pipeline asset
AGEN2373 (CD137 Agonist)	Agenus	Not specified	Pipeline asset
AGENT-797 (iNKT Cell Therapy)	Agenus	Not specified	Pipeline asset